239 related articles for article (PubMed ID: 29620510)
21. Clinicopathological Features of Idiopathic Membranous Nephropathy in 33 Adolescents.
Li C; Li H; Wen YB; Li JN; Lin WF; Cai JF; Duan L; Li Y; Li XM; Li XW
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):544-551. PubMed ID: 28877834
[TBL] [Abstract][Full Text] [Related]
22. Combination of rituximab and short-term glucocorticoids in the treatment of anti-phospholipase A
Ma Q; Li M; Xu G
Clin Exp Med; 2023 Dec; 23(8):5337-5343. PubMed ID: 37688683
[TBL] [Abstract][Full Text] [Related]
23. Rituximab in idiopathic membranous nephropathy.
Ruggenenti P; Cravedi P; Chianca A; Perna A; Ruggiero B; Gaspari F; Rambaldi A; Marasà M; Remuzzi G
J Am Soc Nephrol; 2012 Aug; 23(8):1416-25. PubMed ID: 22822077
[TBL] [Abstract][Full Text] [Related]
24. Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.
Malatesta-Muncher R; Eldin KW; Beck LH; Michael M
Pediatr Nephrol; 2018 Jun; 33(6):1089-1092. PubMed ID: 29546599
[TBL] [Abstract][Full Text] [Related]
25. Rituximab for the second- and third-line therapy of idiopathic membranous nephropathy: a prospective single center study using a new treatment strategy.
Busch M; Rüster C; Schinköthe C; Gerth J; Wolf G
Clin Nephrol; 2013 Aug; 80(2):105-13. PubMed ID: 23587125
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study.
Zhang S; Huang J; Dong J; Li Z; Sun M; Sun Y; Chen B
Front Immunol; 2023; 14():1156470. PubMed ID: 37187749
[TBL] [Abstract][Full Text] [Related]
27. Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series.
Cortazar FB; Leaf DE; Owens CT; Laliberte K; Pendergraft WF; Niles JL
BMC Nephrol; 2017 Feb; 18(1):44. PubMed ID: 28143416
[TBL] [Abstract][Full Text] [Related]
28. A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).
Fervenza FC; Canetta PA; Barbour SJ; Lafayette RA; Rovin BH; Aslam N; Hladunewich MA; Irazabal MV; Sethi S; Gipson DS; Reich HN; Brenchley P; Kretzler M; Radhakrishnan J; Hebert LA; Gipson PE; Thomas LF; McCarthy ET; Appel GB; Jefferson JA; Eirin A; Lieske JC; Hogan MC; Greene EL; Dillon JJ; Leung N; Sedor JR; Rizk DV; Blumenthal SS; Lasic LB; Juncos LA; Green DF; Simon J; Sussman AN; Philibert D; Cattran DC;
Nephron; 2015; 130(3):159-68. PubMed ID: 26087670
[TBL] [Abstract][Full Text] [Related]
29. Rituximab treatment for refractory nephrotic syndrome in adults: a multicenter retrospective study.
Ma X; Fang L; Sheng L; Zhou X; Bai S; Zang X; Wang Y; Li M; Lv Z; Zhong Q; Yang X; Wang Y; Hu Y; Yan D; Shi Y; Chen H; Li J; Tao M; Zhuang S; Wang Y; Liu N
Ren Fail; 2023 Dec; 45(1):2237124. PubMed ID: 37482915
[TBL] [Abstract][Full Text] [Related]
30. Rituximab for the management of idiopathic membranous nephropathy: a meta-analysis.
Huang L; Dong QR; Zhao YJ; Hu GC
Int Urol Nephrol; 2021 Jan; 53(1):111-119. PubMed ID: 32944889
[TBL] [Abstract][Full Text] [Related]
31. Immunosuppressive treatment for nephrotic idiopathic membranous nephropathy: a meta-analysis based on Chinese adults.
Xie G; Xu J; Ye C; Chen D; Xu C; Yang L; Ma Y; Hu X; Li L; Sun L; Zhao X; Mao Z; Mei C
PLoS One; 2012; 7(9):e44330. PubMed ID: 22957065
[TBL] [Abstract][Full Text] [Related]
32. Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature.
Kong WY; Swaminathan R; Irish A
Int Urol Nephrol; 2013 Jun; 45(3):795-802. PubMed ID: 22798030
[TBL] [Abstract][Full Text] [Related]
33. Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis.
Ren S; Wang Y; Xian L; Toyama T; Jardine M; Li G; Perkovic V; Hong D
PLoS One; 2017; 12(9):e0184398. PubMed ID: 28898290
[TBL] [Abstract][Full Text] [Related]
34. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.
Fervenza FC; Abraham RS; Erickson SB; Irazabal MV; Eirin A; Specks U; Nachman PH; Bergstralh EJ; Leung N; Cosio FG; Hogan MC; Dillon JJ; Hickson LJ; Li X; Cattran DC;
Clin J Am Soc Nephrol; 2010 Dec; 5(12):2188-98. PubMed ID: 20705965
[TBL] [Abstract][Full Text] [Related]
35. Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series.
Madan A; Mijovic-Das S; Stankovic A; Teehan G; Milward AS; Khastgir A
BMC Nephrol; 2016 Mar; 17():37. PubMed ID: 27036111
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of low or heavy rituximab‑based protocols and comparison with seven regimens in idiopathic membranous nephropathy: a systematic review and network meta-analysis.
Chen M; Zhang X; Xiong Y; Xu G
Int Urol Nephrol; 2023 Mar; 55(3):641-651. PubMed ID: 36161550
[TBL] [Abstract][Full Text] [Related]
37. Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort.
Wang X; Cui Z; Zhang YM; Qu Z; Wang F; Meng LQ; Cheng XY; Liu G; Zhou FD; Zhao MH
Nephrol Dial Transplant; 2018 Sep; 33(9):1558-1563. PubMed ID: 29149305
[TBL] [Abstract][Full Text] [Related]
38. Immunosuppression therapy for idiopathic membranous nephropathy: systematic review with network meta-analysis.
Bose B; Chung EYM; Hong R; Strippoli GFM; Johnson DW; Yang WL; Badve SV; Palmer SC
J Nephrol; 2022 May; 35(4):1159-1170. PubMed ID: 35199314
[TBL] [Abstract][Full Text] [Related]
39. Primary membranous nephropathy in children and adolescents: a single-centre report from South Asia.
Ramachandran R; Nayak S; Kumar V; Kumar A; Agrawal N; Bansal R; Tiewsoh K; Nada R; Rathi M; Kohli HS
Pediatr Nephrol; 2021 May; 36(5):1217-1226. PubMed ID: 33108509
[TBL] [Abstract][Full Text] [Related]
40. Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience.
Bagchi S; Subbiah AK; Bhowmik D; Mahajan S; Yadav RK; Kalaivani M; Singh G; Dinda A; Kumar Agarwal S
Clin Kidney J; 2018 Jun; 11(3):337-341. PubMed ID: 29942496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
